Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease |
| |
| Authors: | Alan M. Mellow Trey Sunderland Robert M. Cohen Brian A. Lawlor James L. Hill Paul A. Newhouse Martin R. Cohen Dennis L. Murphy |
| |
| Affiliation: | (1) Unit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 20892 Bethesda, MD, USA;(2) Section on Clinical Brain Imaging, Laboratory of Cerebral Metabolism, National Institute of Mental Health, 20892 Bethesda, MD, USA;(3) Ensor Research Laboratory, William S. Hall Psychiatric Institute, University of South Carolina School of Medicine, 29028 Columbia, SC, USA;(4) Present address: Department of Psychiatry, University of Michigan Medical Center, 48109 Ann Arbor, MI, USA;(5) Present address: Department of Psychiatry, University of Vermont College of Medicine, 05405 Burlington, VT, USA;(6) Neuroscience Laboratory, University of Michigan, 1103 East Huron, 48104-1687 Ann Arbor, MI, USA |
| |
| Abstract: | Thyrotropin releasing hormone (TRH) was administered intravenously to ten patients with Alzheimer's Disease (AD) in a high-dose paradigm, thought to maximize central nervous system effects and potentially produce facilitation of cholinergic function, a known property of the neuropeptide. Acute effects of TRH on behavioral, cognitive and physiologic measures were assessed after patients received 0.1 mg/kg TRH, 0.3 mg/kg TRH and placebo, the higher TRH dose and placebo being given in a randomized, double-blind fashion. Patients showed statistically significant increases in arousal and improvement in affect, as well as a modest improvement in semantic memory, all after receiving the higher TRH dose. Both TRH doses produced transient rises in systolic blood pressure, with no effect on diastolic blood pressure, heart rate or temperature. This study suggests that high-dose TRH can be safely administered to AD patients and is neurobehaviorally active; further studies are needed to determine the extent and mechanism of the cognitive and psychobiological properties of this peptide in AD and other neuropsychiatric disorders. |
| |
| Keywords: | Thyrotropin releasing hormone Alzheimer's Disease Neuropeptides |
| 本文献已被 SpringerLink 等数据库收录！ |
|
